Issue of Equity

RNS Number : 0230L

e-Therapeutics plc

29 April 2010

 



e-Therapeutics plc

('e-Therapeutics' or 'the Company')

Issue of Equity and Director's award of Options

e-Therapeutics plc (AIM: ETX), the systems biology drug discovery company, announces that on 28 April 2010 , the Company issued and allotted 466,460 ordinary shares of 0.1p each in the Company (' Ordinary Shares') in order to satisfy the exercise of certain options.

Application has been made to admit the new Ordinary Shares to trading on AIM and dealings in the new Ordinary Shares are expected to commence on 5 May 2010. Following admission the number of Ordinary Shares in issue in the Company will be 65,886,752.

The above figure (65,886,752 Ordinary Shares) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, e-Therapeutics plc under the FSA's Disclosure and Transparency Rules.

In addition to the above, two directors of the Company being Mr Oliver James and Mr Brad Hoy were both granted option over 25,000 ordinary shares in the Company at an exercise price of £0.385 and which have a vesting period of 3 years. Following this grant Mr James and Mr Hoy have the following interests in ordinary shares of the Company:

Name	Ordinary Shares owned	Options over Ordinary Shares
	Number	Number	Exercise Price	Date at which exercisable
Oliver James	38,500	118,020	£0.67	Vested
		25,000	£0.385	28 April 2013
Brad Hoy		80,000	£0.375	Vested
		25,000	£0.385	28 April 2013

- Ends -

For more information:
e-Therapeutics plc	www.etherapeutics.co.uk
Malcolm Young [e-mail]	[phone]
Nominated Advisor & Broker: Canaccord Adams Ltd	www.canaccordadams.com
Robert Finlay / Henry Fitzgerald-O'Connor henry.fitzgerald-o'[e-mail]	[phone]
Media enquiries: Abchurch Communications	www.abchurch-group.com
Heather Salmond / Simone Elviss / Hannah Sharman [e-mail]	[phone]

 

END

 

 

IOESEFSAUFSSESL